Exelixis
EXEL
#1694
Rank
โ‚น1.073 T
Marketcap
โ‚น3,988
Share price
-0.02%
Change (1 day)
33.92%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): โ‚น205.34

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น213.95. In 2023 the company made an earnings per share (EPS) of โ‚น58.73 an increase over its 2022 EPS that were of โ‚น51.24.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น205.34
2023โ‚น58.7314.61%
2022โ‚น51.24-22.97%
2021โ‚น66.52100%
2020โ‚น33.26-65.09%
2019โ‚น95.29-53.91%
2018โ‚น206.76333.96%
2017โ‚น47.64-260.61%
2016-โ‚น29.67-58.75%
2015-โ‚น71.92-42.45%
2014-โ‚น124.965.3%
2013-โ‚น118.66

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
GlaxoSmithKline
GSK
โ‚น323.26 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
โ‚น333.13 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น682.65 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น266.99 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,171 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
โ‚น938.46 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น154.62-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
-โ‚น329.92-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น75.51-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA